目的 观察连花清瘟胶囊联合头孢哌酮钠舒巴坦钠治疗社区获得性肺炎的临床疗效。方法 选取2016年1月—2016年12月海南医学院第一附属医院接诊的社区获得性肺炎患者106例，随机分成对照组和治疗组，每组各53例。对照组静脉滴注注射用头孢哌酮钠舒巴坦钠，2 g加入生理盐水250 mL，1次/12 h；治疗组在对照组的基础上口服连花清瘟胶囊，4粒/次，3次/d。两组均连续治疗10 d。评价治疗后两组患者临床疗效，同时比较治疗前后两组临床症状体征和胸片改善情况以及白细胞计数（WBC）、中粒细胞百分比（N%）和高敏C反应蛋白（hs-CRP）水平变化。结果 治疗后，对照组和治疗组总有效率分别为81.13%、92.45%，两组比较差异具有统计学意义（P< 0.05）。治疗后，治疗组患者体温恢复时间、咳嗽症状消失时间、湿性啰音体征消失时间均比对照组明显缩短，两组比较差异具有统计学意义（P< 0.05）。治疗后，对照组胸片改善总有效率为83.02%，显著低于治疗组的94.34%，两组比较差异具有统计学意义（P< 0.05）。治疗后，两组WBC、N%和hs-CRP指标水平显著低于治疗前，同组比较差异具有统计学意义（P< 0.05）；且治疗组上述指标水平明显好于对照组，两组比较差异具有统计学意义（P< 0.05）。结论 连花清瘟胶囊联合头孢哌酮钠舒巴坦钠可明显改善社区获得性肺炎患者临床症状体征和胸片结果，不良反应较少，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Lianhua Qingwen Capsules combined with cefoperazone sodium and sulbactam sodium in treatment of community acquired pneumonia. Methods Patients (106 cases) with community acquired pneumonia from January 2016 to December 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 2 g added into 250 mL normal saline, once every 12 h. Patients in the treatment group were po administered with Lianhua Qingwen Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 10 d. After treatment, clinical efficacy was evaluated, and the improvement of the clinical symptoms and chest X-ray, the levels of WBC, N%, and hs-CRP in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 92.45%, respectively, and there were differences between two groups (P < 0.05). After treatment, the body temperature recovery time, cough symptom, and wet rale disappearance time were significantly shorter than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the improvement of chest X-ray in the control group was 83.02%, which was significantly lower than 94.34% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the WBC, N%, and hs-CRP levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these indicators levels in treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Lianhua Qingwen Capsules combined with cefoperazone sodium and sulbactam sodium can obviously improve the clinical symptoms, signs and chest X-ray in treatment of community acquired pneumonia with less adverse reactions, which has a certain clinical application value.